Objective determination of the oncolytic potency of conditionally- replicating adenoviruses using mathematical modeling
Journal of Gene Medicine , Volume 12 - Issue 7 p. 564- 571
Background: Conditionally-replicating adenoviruses (CRAds) infect and replicate in tumor cells, releasing viral progeny upon lysis of the cell. This is a dynamic and inherently exponential process and, thus, the assessment of CRAds should incorporate these dynamics. In vitro experiments are therefore prone to subjective assessment because no validated assay exists that truly appreciates the dynamics of the process. An objective assay could simplify experiments and reduce the number of CRAd variants required to enter a full preclinical evaluation. Methods: We developed a simple and practical mathematical model incorporating easily obtainable parameters of the interaction between replicating viruses and growing tumor cells in vitro and, in the present study, validate this model by fitting the predicted values to experimentally-derived values. Results: From the exponential curves of cellular growth and the viral propagation rate in glioma cells, we derive the four parameters needed in this model and show a robust fit to experimental data. Because the initial infection conditions appear to significantly influence the final outcome of CRAd experiments, these conditions are determined using the same cells and correlated with the expression of the primary adenovirus receptor CAR (coxsackie and adenovirus receptor). Conclusions: The results obtained shed light upon the method of action of CRAds and provide an objective and practical model and assay for determining and predicting CRAd activity in tumor cells.
|, , , , , , , , , , , , , , , , , , , , , , , ,|
|Journal of Gene Medicine|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Idema, S, Dirven, C.M.F, Beusechem, V.W, Beuschem, V.W, Carette, J.E, Planqúe, R, … Vandertop, W.P. (2010). Objective determination of the oncolytic potency of conditionally- replicating adenoviruses using mathematical modeling. Journal of Gene Medicine, 12(7), 564–571. doi:10.1002/jgm.1468